Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.87 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.73 |
| ▸ | NPC1 | O15118 | 2/20 | 0.69 |
| ▸ | RAB9A | P51151 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.61 |
| ▸ | CTSG | P08311 | 1/20 | 0.61 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.61 |
| ▸ | CMA1 | P23946 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | NAAA | Q02083 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4552855 | 0.95 | HPGD (0.79) | HPGDSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL30910449 | 0.90 | SMN1; SMN2 (0.87) | HPGDSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL15577818 | 0.90 | SMN1; SMN2 (0.87) | HPGDSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL4039186 | 0.89 | ALDH1A1 (0.83) | HPGDSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL23470985 | 0.87 | HPGD (0.73) | HPGDSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL25970084 | 0.86 | SMN1; SMN2 (0.96) | HPGDSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL20734830 | 0.85 | SMN1; SMN2 (1.00) | HPGDSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL23470996 | 0.84 | HPGD (0.65) | HPGDSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL19196157 | 0.84 | SMN1; SMN2 (0.67) | HPGDSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL13531416 | 0.84 | HPGD (0.73) | HPGDSMN1; SMN2NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112752760-B | Heterocyclic compounds | 武田药品工业株式会社 | 2024-01-19 | — | — | CN | claimed |
| EP-4188551-A1 | ARYL SUBSTITUTED PYRROLO-PYRIDINONES AND THERAPEUTIC USES THEREOF | Bayer Aktiengesellschaft (DE) | 2023-06-07 | — | — | EP | claimed |
| CN-116217352-A | Method for preparing cannabigerol and analogues thereof | 上海中医药大学 | 2023-06-06 | — | — | CN | claimed |
| CN-113135922-B | Azepane [4,3,2-cd ] isoindol-2-one derivatives and application thereof | 中国药科大学 | 2023-05-30 | — | — | CN | claimed |
| EP-4139286-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | Bayer Aktiengesellschaft (DE) | 2023-03-01 | — | — | EP | claimed |
| EP-3612527-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS | TAKEDA PHARMACEUTICALS CO (JP) | 2022-07-20 | — | — | EP | claimed |
| CN-109415381-B | Thiazolopyridine derivatives as GPR119 agonists | 人类制药有限公司 | 2022-03-25 | — | — | CN | claimed |
| CN-113135922-A | Azacycloheptane [4,3,2-cd ] isoindol-2-one derivatives and application thereof | 中国药科大学 | 2021-07-20 | — | — | CN | claimed |
| CN-109310668-A | Positive allosteric modulators of muscarinic acetylcholine receptor M4 | 范德比尔特大学 | 2019-02-05 | — | — | CN | claimed |
| CN-103608350-B | Triazolopyridine compounds | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-25 | — | — | CN | claimed |
| EP-1831183-A1 | 1,6-SUBSTITUTED (3R,6R)-3-(2,3-DIHYDRO-1H-INDEN-2-YL)-2,5-PIPERAZINEDIONE DERIVATIVES AS OXYTOCIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PRE-TERM LABOUR, DYSMENORRHEA AND ENDOMETRIOSIS | GLAXO GROUP LIMITED (GB) | 2007-09-12 | — | — | EP | claimed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | claimed |
| WO-2006119821-A1 | AGENT FOR DYEING KERATIN-BASED FIBRES | HENKEL KOMMANDITGESELLCHAFT AUF AKTIEN (DE) | 2006-11-16 | — | — | WO | claimed |
| WO-2006067462-A1 | 1,6 - SUBSTITUTED (3R,6R) -3- (2,3-DIHYDRO-1H-INDEN-2-YL)-2,5-PIPERAZINEDIONE DERIVATIVES AS OXYTOCIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PRE-TERM LABOUR, DYSMENORRHEA AND ENDOMETRIOSIS | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | claimed |
| US-6030984-A | 7-(4-PHENOXYPHENYL)-6-OXOQUINOLIZINES AND DERIVATIVES OF TRICYCLIC RING ANALOGUES, PARTICULARLY 7-OXOTHIENO-(2,3-A)QUINOLIZINE; INHIBITING BETA-AMYLOID PEPTIDE ACTIVITY | HOFFMANN-LA ROCHE INC. (US) | 2000-02-29 | — | — | US | claimed |
| US-5869500-A | INHIBITING BETA-AMYLOID PEPTIDE ACTIVITY | HOFFMANN-LA ROCHE INC. (US) | 1999-02-09 | — | — | US | claimed |
| WO-1998025930-A2 | USE OF BI- AND TRICYCLIC PYRIDONE DERIVATIVES AGAINST ALZHEIMER'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 1998-06-18 | — | — | WO | claimed |
| EP-0339976-B1 | Anti-tumour agents | ICI PLC (GB) | 1994-02-02 | — | — | EP | claimed |
| EP-0339976-A1 | Anti-tumour agents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-11-02 | — | — | EP | claimed |
| US-4705805-A | O,O*-DITHIOBIS/BENZAMIDES/ | KYOWA HAKKO KOGYO CO., LTD., (JP) | 1987-11-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | HPGD 3765/4885SMN1; SMN2 4705/4885NPC1 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.